Literature DB >> 2663302

Clinical pharmacokinetics of zidovudine. An overview of current data.

J M Collins1, J D Unadkat.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1989        PMID： 2663302     DOI： 10.2165/00003088-198917010-00001

Source DB:  PubMed          Journal:  Clin Pharmacokinet        ISSN： 0312-5963            Impact factor:   6.447


× No keyword cloud information.
  21 in total

1.  Pyrimidine dideoxyribonucleosides: selectivity of penetration into cerebrospinal fluid.

Authors:  J M Collins; R W Klecker; J A Kelley; J S Roth; C L McCully; F M Balis; D G Poplack
Journal:  J Pharmacol Exp Ther       Date:  1988-05       Impact factor: 4.030

2.  Estimation of population characteristics of pharmacokinetic parameters from routine clinical data.

Authors:  L B Sheiner; B Rosenberg; V V Marathe
Journal:  J Pharmacokinet Biopharm       Date:  1977-10

3.  Pharmacokinetics and bioavailability of zidovudine in humans.

Authors:  M R Blum; S H Liao; S S Good; P de Miranda
Journal:  Am J Med       Date:  1988-08-29       Impact factor: 4.965

Review 4.  Developmental aspects of drug conjugation, with special reference to glucuronidation.

Authors:  G J Dutton
Journal:  Annu Rev Pharmacol Toxicol       Date:  1978       Impact factor: 13.820

5.  Administration of 3'-azido-3'-deoxythymidine, an inhibitor of HTLV-III/LAV replication, to patients with AIDS or AIDS-related complex.

Authors:  R Yarchoan; R W Klecker; K J Weinhold; P D Markham; H K Lyerly; D T Durack; E Gelmann; S N Lehrman; R M Blum; D W Barry
Journal:  Lancet       Date:  1986-03-15       Impact factor: 79.321

Review 6.  Zidovudine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy.

Authors:  H D Langtry; D M Campoli-Richards
Journal:  Drugs       Date:  1989-04       Impact factor: 9.546

7.  Plasma and cerebrospinal fluid pharmacokinetics of 3'-azido-3'-deoxythymidine: a novel pyrimidine analog with potential application for the treatment of patients with AIDS and related diseases.

Authors:  R W Klecker; J M Collins; R Yarchoan; R Thomas; J F Jenkins; S Broder; C E Myers
Journal:  Clin Pharmacol Ther       Date:  1987-04       Impact factor: 6.875

8.  Concurrent zidovudine levels in semen and serum determined by radioimmunoassay in patients with AIDS or AIDS-related complex.

Authors:  K Henry; B J Chinnock; R P Quinn; C V Fletcher; P de Miranda; H H Balfour
Journal:  JAMA       Date:  1988-05-27       Impact factor: 56.272

9.  Toxicity of 3'-azido-3'-deoxythymidine and 9-(1,3-dihydroxy-2-propoxymethyl)guanine for normal human hematopoietic progenitor cells in vitro.

Authors:  J P Sommadossi; R Carlisle
Journal:  Antimicrob Agents Chemother       Date:  1987-03       Impact factor: 5.191

10.  Phosphorylation of 3'-azido-3'-deoxythymidine and selective interaction of the 5'-triphosphate with human immunodeficiency virus reverse transcriptase.

Authors:  P A Furman; J A Fyfe; M H St Clair; K Weinhold; J L Rideout; G A Freeman; S N Lehrman; D P Bolognesi; S Broder; H Mitsuya
Journal:  Proc Natl Acad Sci U S A       Date:  1986-11       Impact factor: 11.205
View more
  31 in total

1.  A swift and facile radiosynthesis of [alpha-32P]-3'-azido-3'-deoxythymidine 5'-triphosphate (AZT triphosphate).

Authors:  P F Torrence; T Kovács
Journal:  Nucleic Acids Res       Date:  1990-11-25       Impact factor: 16.971

2.  Decreased and variable systemic availability of zidovudine in patients with AIDS if administered with a meal.

Authors:  E Lotterer; M Ruhnke; M Trautmann; R Beyer; F E Bauer
Journal:  Eur J Clin Pharmacol       Date:  1991       Impact factor: 2.953

Review 3.  Pharmacokinetics of newer drugs in patients with renal impairment (Part I).

Authors:  J P Fillastre; E Singlas
Journal:  Clin Pharmacokinet       Date:  1991-04       Impact factor: 6.447

4.  Development of a Novel Maternal-Fetal Physiologically Based Pharmacokinetic Model I: Insights into Factors that Determine Fetal Drug Exposure through Simulations and Sensitivity Analyses.

Authors:  Zufei Zhang; Marjorie Z Imperial; Gabriela I Patilea-Vrana; Janak Wedagedera; Lu Gaohua; Jashvant D Unadkat
Journal:  Drug Metab Dispos       Date:  2017-06-06       Impact factor: 3.922

5.  Development of a Novel Maternal-Fetal Physiologically Based Pharmacokinetic Model II: Verification of the model for passive placental permeability drugs.

Authors:  Zufei Zhang; Jashvant D Unadkat
Journal:  Drug Metab Dispos       Date:  2017-01-03       Impact factor: 3.922

Review 6.  Zidovudine. An update of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy.

Authors:  Michelle I Wilde; Heather D Langtry
Journal:  Drugs       Date:  1993-09       Impact factor: 9.546

7.  Effect of age on distribution of zidovudine (azidothymidine) into the cerebrospinal fluid of Macaca nemestrina.

Authors:  A Lopez-Anaya; J D Unadkat; D F Calkins; A L Smith
Journal:  Pharm Res       Date:  1993-09       Impact factor: 4.200

8.  Pharmacokinetic interaction between rifampin and zidovudine.

Authors:  D M Burger; P L Meenhorst; C H Koks; J H Beijnen
Journal:  Antimicrob Agents Chemother       Date:  1993-07       Impact factor: 5.191

9.  Pharmacokinetics of zidovudine after the initial single dose and during chronic-dose therapy in HIV-infected patients.

Authors:  K Gallicano; J Sahai; E Ormsby; D W Cameron; A Pakuts; I McGilveray
Journal:  Br J Clin Pharmacol       Date:  1993-08       Impact factor: 4.335

10.  Pharmacokinetics of the anti-human immunodeficiency virus nucleoside analog stavudine in cynomolgus monkeys.

Authors:  S Kaul; K A Dandekar
Journal:  Antimicrob Agents Chemother       Date:  1993-05       Impact factor: 5.191
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.